Aachen (ots) - - Latest step in Grünenthal’s strategy to acquire established medicines that serve clear medical needs, leverage its commercial and operational capabilities, and drive growth. - Stivarga® (regorafenib) is an established oral treatment for certain advanced cancers, including metastatic colorectal cancer, gastrointestinal stromal tumours (GIST) and hepatocellular carcinoma (liver cancer). It is approved ...
Aachen (ots) - - The investigational compound has a unique mechanism of action and the potential to become a first-in-class therapy option for the treatment of acute and chronic pain. - In a Phase I trial, the investigational compound was demonstrated to be safe and well tolerated. - A Phase II trial will commence later this year. Grünenthal announced today that the ...
LTS Lohmann Therapie-Systeme AG
Andernach (ots) - LTS LOHMANN Therapie-Systeme AG (“LTS”), a leading pharmaceutical technology company specializing in advanced drug delivery systems, today announced the expansion of its service portfolio to include CDMO services for ophthalmic drug delivery solutions, with manufacturing capacities located in the United States at LTS’ Lakewood, New Jersey facility. The new offering focuses initially on product ...
Aachen, Germany & Yeoju, South Korea (ots) - Grünenthal, a global leader in pain management and related diseases, and BCWorld Pharm Co., Ltd. ("BCWP"), a specialty company actively expanding and diversifying its pain management portfolio through global open innovation partnerships, announced today that they have entered into a definitive agreement whereby BCWP will ...
Aachen, Germany (ots) - - Grünenthal acquired Kyowa Kirin International's 49% stake in 'Grünenthal Meds', a joint venture formed in 2023 to market the established medicines portfolio from Kyowa Kirin International. - Through this acquisition, Grünenthal assumes the sole responsibility of a portfolio comprising 12 ...
Aachen, Germany & Victoria, Australia (ots) - Grünenthal, a global leader in pain management and related diseases, and Clinect Pty Ltd ("Clinect"), an Australian based company focussed on supporting access to unique products, announced today that they have entered into a definitive agreement whereby Clinect will have the exclusive Australian rights to Qutenza®, a ...
Aachen, Germany & Toronto, Canada (ots) - Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, today announced they have entered into a licensing agreement whereby Apotex will have the exclusive Canadian rights to ...
Aachen (ots) - Grünenthal PRO, the contract development and manufacturing organization (CDMO) division of Grünenthal offering a range of services including final assembly of autoinjectors, is entering into a non-exclusive partnership with SHL Medical, a world-leading solutions provider of advanced drug delivery ...
ABDA - Bundesvereinigung Deutscher Apothekerverbände e. V.
Berlin (ots) - ABDA – Federal Union of German Associations of Pharmacists has released the Statistical Yearbook “German Pharmacies: Figures, Data, Facts 2025”. The publication offers a comprehensive overview of the latest trends in the pharmaceutical and healthcare sectors in Germany and beyond. It shows that the number of pharmacies has decreased again. At the ...
LTS Lohmann Therapie-Systeme AG
Andernach / Montreal (ots) - LTS LOHMANN Therapie-Systeme AG (LTS), a leading pharmaceutical technology company, and Nualtis (formerly IntelGenx Corp.), an innovator in oral thin film (OTF) drug delivery technology, today announced a strategic collaboration to provide customers with robust, reliable, high-quality ...
Düsseldorf (ots) - - Revenues +11.6%, Adjusted EBITDA +13.1% - Organic development compared to pro forma figures Q1 2024: revenues -6.5%, adjusted EBITDA -9.3% - Q1 significantly influenced by revenue shift in syringe business - Guidance 2025 confirmed: organic revenue growth of 3-5% and adjusted EBITDA margin of 22% Gerresheimer, an innovative systems and solutions provider and global partner for the pharma, biotech and ...
Aachen, Germany/Morristown, N.J. (ots) - - The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures[1], thus affecting more than 3 million people with surgical procedures ...
Munich / Paris / Tokyo (ots) - - Adragos Pharma now third largest pure-play CDMO in the Japanese market - Long-term agreement with Sanofi secures local healthcare supply Munich-based pharmaceutical contract manufacturer (CDMO) Adragos Pharma GmbH successfully completed the acquisition of one of Japan's leading ...
Baltimore, MD (ots) - Sysmex Inostics, a global leader in the liquid biopsy revolution for oncology, announces the use of their HPV-SEQ test in the prospective University of Chicago clinical trial,1 “Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer.” “The ability to reliably detect HPV-DNA ...
Freiburg (ots) - Eleva, a manufacturer of superior biologics, is entering clinical phases with its own drug candidates, such as immune-regulating factor H, as well as in collaboration with pharmaceutical partners. Its moss-based platform is ideally suited to produce difficult-to-express but therapeutically promising drug candidates. Its recently expanded production ...
Strausberg (ots) - Aresus Pharma GmbH, a company of DERMAGO Holding GmbH, announced today that the abstract "Inhibition of cell-proliferation and cell viability by Polyphenon E ® (Veregen®) in cutaneous SCC cell lines" has been accepted as an e-poster short presentation at the 31st German Skin Cancer Congress. In ...
European Association of E-Pharmacies (EAEP)
Brussels/Berlin (ots) - The leading association of European online pharmacies has a new board team, a new name and a new external image: Walter Hess, Head Germany in the Group Management of the Zur Rose Group and CEO of DocMorris N.V., is now president of the association and Stefan Feltens, CEO SHOP APOTHEKE EUROPE, ...
Freiburg (ots) - Eleva, a manufacturer of superior biologics, has secured up to EUR 60 million in funding from Zukunftsfonds Heilbronn (ZFHN). The funds will help advance one of its drug candidates, CPV-101, to stages that will facilitate further investment from venture capitalists and/or pharmaceutical companies. Eleva also announced the addition of Dr. Ralf Smit to ...
Freiburg (ots) - Eleva, a manufacturer of superior biologics, is exploring the potential of one of its drug candidates for first-in-line therapy of Covid-19. The compound, factor H, is part of the complement system, which is believed to affect the severity of the course of Covid-19. Eleva has developed factor H previously for a different indication and taken it through ...
Greenville South Carolina (ots) - A previously untested approach to preventing the most severe outcomes of lung diseases, including COVID-19, has been developed by Elastrin Therapeutics based on targeting damaged elastic fiber that leads to impaired lung function. The company has developed the world's first ...
Hamburg, Germany and Baltimore, Maryland (ots) - Sysmex Inostics announces the availability of the SafeSEQ Breast Cancer and Head and Neck Cancer Panels along with the SafeSEQ Rapid Custom Development program for circulating tumor DNA (ctDNA) analysis. SafeSEQ is a next-generation sequencing (NGS)-based approach that delivers sensitivity comparable to the clinically ...
Eckert & Ziegler Strahlen und Medizintechnik AG
Berlin (ots) - Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) is engaging with a USA based biotech company to become a contract manufacturer for a new type of cancer treatment and is creating a new production plant for this purpose at its Braunschweig location with financial support provided by the customer. The cooperation enfolds a brand-new ...
CGC - Cramer-PR im Gesundheitswesen
Weinheim/Germany (ots) - International biotechnology firm Cytonet announced today that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) seeking approval for its liver cell therapy for the treatment of Urea Cycle Disorders (UCD) in children. UCD is a life-threatening ...
